Actualités de Amsterdam

Filtre
  • 03.04.2012 – 10:03

    Atradius N.V.

    Atradius Collections Increases Customer Satisfaction for Third Year in a Row

    Amsterdam (ots/PRNewswire) - ? Atradius Collections released the results of its recent customer satisfaction survey revealing outscoring the results of the previous three years. The survey is conducted annually and investigates customer views on Atradius Collections' performance in national and international debt collections. The overall survey satisfaction score of ...

  • 16.12.2011 – 14:23

    NTT Europe Ltd

    NTT Europe Expands Global IP Network With new PoP in EvoSwitch Datacentre, Amsterdam

    London and Amsterdam (ots/PRNewswire) - NTT Europe consolidates European footprint amid plans for eastern European expansion NTT Europe, a wholly owned subsidiary of NTT Communications Corporation [http://www.ntt.com/index-e.html ] (NTT Com), announced today that it has expanded the reach of the NTT Communications' Tier 1 Global IP Network in Europe with a new Point of ...

  • 24.10.2011 – 09:38

    Agendia B.V.

    Agendia Appoints New CEO and Supervisory Board Member

    Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular diagnostics company, today announced that its supervisory board of directors has appointed David Macdonald as chief executive officer. This follows the resignation of the company's co-founder and chief executive officer, Dr. Bernhard Sixt. Dr. Sixt will remain with the company in an advisory capacity. Agendia also announced the addition ...

  • 18.10.2011 – 15:03

    Agendia B.V.

    EORTC, BIG, and Agendia Announce Completion of Patient Recruitment for International MINDACT Study

    BRUSSELS, IRVINE, California, and AMSTERDAM, October 18, 2011 (ots/PRNewswire) -- The EORTC, BIG, and Agendia, a commercial-stage molecular cancer diagnostics company, today announced the completion of patient registration for the EORTC 10041/BIG3-04 MINDACT (Microarray In Node negative and 1-3 positive lymph node Disease may Avoid Chemotherapy Trial) study. More than ...

  • 06.10.2011 – 09:00

    Synova S.A.

    Synova S.A. attracts CHF 20m in growth capital from HPE

    Ecublens, Switzerland / Amsterdam, the Netherlands (ots) - Holland Private Equity ("HPE") invested substantial primary capital in Synova S.A. ("Synova") in a capital increase of up to CHF 20 million to become its largest outside shareholder. The expansion capital will allow Synova to further execute its internationalization, sales expansion and fuel further product development of its unique water-jet guided laser cutting ...

  • 03.10.2011 – 15:03

    Agendia B.V.

    Agendia Successfully Completes Bi-Annual FDA Inspection

    Irvine, California and Amsterdam (ots/PRNewswire) - Agendia, an innovative molecular cancer diagnostics company, today announced that the company successfully completed a recent, routine inspection of its Irvine, California-based laboratories by the US Food and Drug Administration (FDA). Agendia received FDA 510(k) clearance for its MammaPrint(R) breast cancer recurrence test in early 2007. It remains the first and only ...

  • 20.09.2011 – 11:02

    Layar

    Layar Enters in Partnership With Telefonica I+D for Visual Search Technology

    Amsterdam (ots/PRNewswire) - Layar, the largest open platform for mobile augmented reality (AR), today announced they entered into a strategic partnership with Telefonica I+D for providing them with their market leading Visual Search Technology: IRIS. Visual Search enables Layar to search through millions of images to identify these images and correctly augment them on ...

  • 19.09.2011 – 15:09

    Agendia B.V.

    Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®

    Irvine, California and Amsterdam (ots/PRNewswire) - - Peer-Reviewed Article Notes That Multi-Gene Subtyping Profile Provides Deeper Insight Into Breast Cancer Agendia, an innovative molecular cancer diagnostics company, today announced that a published report highlighting the development and validation of its 80-gene BluePrint breast cancer profile was published online ...